Alimera Sciences

About Alimera Sciences

Alimera Sciences (NASDAQ:ALIM) specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals, focusing primarily on retinal diseases. The company's flagship product, ILUVIEN®, is an implant designed to treat diabetic macular edema, a major cause of vision loss in adults. With an enduring commitment to addressing unmet medical needs in the field of retina care, Alimera continues to expand its product portfolio and reach, aiming to improve the quality of life for patients worldwide by offering innovative treatments. Their projects often involve extensive clinical trials aimed at exploring new therapies and expanding the indications for their current products. Alimera's objective is to be at the forefront of advancements in retinal health, providing solutions that offer long-term benefits to patients suffering from challenging conditions.

What is Alimera Sciences known for?

Snapshot

2003

Year founded

157

Employees

Alpharetta, United States

Head office

Loading Map...

Operations

All Locations

Alpharetta, US

Products and/or services of Alimera Sciences

ILUVIEN, a sustained release implant for treating diabetic macular edema, offering continuous therapy for up to three years.
Research and development efforts focusing on leveraging the proprietary Durasert technology for other ocular diseases.
Global commercialization partnerships aimed at expanding ILUVIEN's presence in international markets, enhancing patient access to treatment.
Continuous post-marketing studies to monitor ILUVIEN's long-term safety and effectiveness, ensuring optimal patient outcomes.
Collaboration with healthcare professionals to provide education and support for the management of retinal diseases using their products.
Engagement in patient advocacy and support initiatives to increase awareness and understanding of treatments available for chronic retinal diseases.